Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
Volume 1.14M
Average 1.17M
BIIB Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Biogen Inc.NASDAQ: BIIB
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue growth accelerates
Q2 FY2026 revenue of $2.74B rose 3.4% year over year, ahead of the -0.5% change in trailing-twelve-month revenue. Sequentially, it rose 10.4% from the prior quarter. Over 3 fiscal years it compounded at -1.2% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 26 analysts of $10.6B (+8.0%) for the fiscal year ending Dec 2026, a step up from the +1.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $2.74B+10.4% QoQ
- Last fiscal yearDec 2025
- $9.81B+1.4% YoY
- LTMJun 2026
- $9.95B-0.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.4% | +7.3% | +3.9 pp |
| 1 year | +1.4% | +8.0% | +6.6 pp |
| 3-year CAGR | -1.2% | +4.3% | +5.5 pp |
| 5-year CAGR | +3.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 9.81B USD
- Year-over-year change
- +1.4%
- 4-year CAGR
- -2.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.81B | +1.4% |
| FY2024 | 2024-12-31 | 9.68B | -1.6% |
| FY2023 | 2023-12-31 | 9.84B | -3.3% |
| FY2022 | 2022-12-31 | 10.17B | -7.4% |
| FY2021 | 2021-12-31 | 10.98B | — |
Revenue vs competitors
How BIIB compares with its peers on the latest reported figures
- BIIB's LTM Jun 2026 revenue of $9.95B is the 7th highest of the 11 companies compared; the peer median is $14.26B.
- Its year-over-year change of -0.5% is the 9th highest of 11, against a peer median of +8.1%.
- Over three fiscal years its annual growth of -1.2% compares with a peer median of +14.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $79.67B | +49.6% | +31.7% | |
| LTM Jun 2026 | $63.7B | -0.2% | -14.8% | |
| LTM Sep 2026 | $62.17B | +7.0% | +9.8% | |
| LTM Jun 2026 | $38.13B | +9.2% | +11.8% | |
| LTM Jun 2026 | $15.53B | +9.3% | +5.6% | |
| LTM Sep 2026 | $12.99B | +10.8% | +10.6% | |
| LTM Jun 2026 | $9.95B | -0.5% | -1.2% | |
| LTM Jun 2026 | $4.8B | +95.1% | +53.0% | |
| LTM Jun 2026 | $3.15B | +2.5% | +18.0% | |
| LTM Jun 2026 | $1.01B | -42.8% | +35.3% | |
| LTM Sep 2026 | $959.76M | -0.7% | +17.1% | |
| Peer median (excluding BIIB) | $14.26B | +8.1% | +14.4% | |
Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.98B | 10.17B | 9.84B | 9.68B | 9.81B |
| Cost of Revenue | 2.11B | 2.28B | 2.53B | 2.31B | 2.9B |
| Gross Profit | 8.87B | 7.9B | 7.3B | 7.37B | 6.91B |
| Gross Margin | 80.8% | 77.6% | 74.2% | 76.1% | 70.5% |
| Research & Development | 3.4B | 2.6B | 2.7B | 2.49B | 1.95B |
| Selling, General & Admin | 2.68B | 2.41B | 2.5B | 2.39B | 2.43B |
| Operating Expenses | 6.08B | 5.01B | 5.2B | 4.88B | 5.04B |
| Depreciation & Amortization | 487.7M | 518.4M | 494.8M | 673.2M | 779.9M |
| EBITDA | 3.92B | 3.54B | 2.38B | 3B | 2.95B |
| EBITDA Margin | 35.7% | 34.8% | 24.2% | 31.0% | 30.0% |
| Operating Income | 2.79B | 2.89B | 2.1B | 2.49B | 1.88B |
| Operating Margin | 25.4% | 28.4% | 21.3% | 25.7% | 19.1% |
| Interest Income | 11M | 89.3M | 276.5M | 67.6M | 87.8M |
| Interest Expense | 253.6M | 246.6M | 246.9M | 250.3M | 246M |
| Other Income / Expenses | (1.01B) | 705.3M | (800.5M) | (584.3M) | (476M) |
| Income Before Tax | 1.78B | 3.59B | 1.3B | 1.91B | 1.4B |
| Pre-Tax Margin | 16.2% | 35.3% | 13.2% | 19.7% | 14.3% |
| Income Tax Expense | 52.5M | 632.8M | 135.3M | 273.8M | 108.11M |
| Net Income | 1.56B | 3.05B | 1.16B | 1.63B | 1.29B |
| Net Margin | 14.2% | 29.9% | 11.8% | 16.9% | 13.2% |
| EPS (Basic) | 10.44 | 20.97 | 8.02 | 11.20 | 8.85 |
| EPS (Diluted) | 10.40 | 20.87 | 7.97 | 11.19 | 8.83 |
| Weighted Avg Shares | 149.1M | 145.3M | 144.7M | 145.7M | 146.7M |
| Weighted Avg Shares (Diluted) | 149.6M | 146M | 145.6M | 145.9M | 146.7M |
Biogen Inc.
NASDAQ:BIIB
Intrinsic Alpha fair value
Locked
Current Price
$251.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.